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Boswellia serrata (BS) is an important traditional medicinal plant that currently represents an interesting topic for pharmaceutical
research since it possesses several pharmacological properties (e.g., anti-inflammatory, antimicrobial, and antitumour). The safety
and versatility of this dietary supplement should allow for its use in numerous pathological conditions; however the quality of
the extracts needs to be standardized to increase the clinical success rate resulting from its use. In the present study, different
commercially available B. serrata extracts were employed to compare their AKBA content and in vitro antioxidant power.
Furthermore, their ability to modulate the immune system regulatory properties was investigated. Our results showed that the
AKBA content varied from 3.83 ± 0.10 to 0.03 ± 0.004%, with one sample in which it was not detectable. The highest antioxidant
power and phenolic content were shown by the same extract, which also exhibited the highest AKBA concentration. Finally, the
BS extracts showed the ability to influence the regulatory and effector T-cell compartments. Our results suggest that frankincense
should be further investigated for its promising potentiality to modulate not only inflammation/oxidative stress but also immune
dysregulation, but attention should be paid to the composition of the commercial extracts.
1. Introduction
The gum resin of Boswellia serrata (BS), a traditional treat-
ment of Ayurvedicmedicine in India also identified as Indian
frankincense, Salai Guggal, or Indian olibanum, has been
used for centuries as a remedy for many health problems [1].
Indeed, the anti-inflammatory, antiarthrogenic, and anal-
gesic activities of its dried resinous gum (guggulu), derived
from tapping the Boswellia tree, have been recognized since
ancient times [2]. The inflammatory response represents
the first-line defense of the body to tissue damage and/or
to microbial invasion and it determines the recruitment of
immune cells and some plasma proteins [3]. The final goal of
inflammation is healing, elimination of the external or inter-
nal inflammation noxae, and the restoration of homeostasis.
This immune response should be self-limiting but the
persistence of the stimulus in predisposed subjects leads to
chronification of the process and eventually to irreversible tis-
sue injury. Indeed, persisting low-grade inflammation plays
a key role in the pathogenesis of many chronic diseases [4]
and most of these diseases are also associated with increased
production of reactive oxygen species (ROS), which results in
oxidative stress [5]. Therefore, inflammation is tightly linked
with oxidative stress [6] by an interdependent relationship
and both participate in the pathogenesis of many chronic
diseases [4].
During recent decades, many authors have investigated
themechanisms of action of BS extracts related to the inflam-
matory process. Studies in animal models showed that the
ingestion of a defatted alcoholic extract ofBoswelliadecreased
polymorphonuclear leukocyte infiltration and migration as
well as primary antibody synthesis [7, 8] and led to almost
total inhibition of the classical complement pathway [9].
In vitro studies revealed that the boswellic acids, a group
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of pentacyclic triterpenoid compounds, and their acetylated
derivatives inhibit the biosynthesis of leukotrienes, the proin-
flammatory 5-lipoxygenase products which cause increased
permeability [10], in a dose dependent manner [11]. In addi-
tion, Cuaz-Pe´rolin et al. [12] observed that 3-acetyl-11-keto-
beta-boswellic acid (AKBA) was a natural inhibitor of the
transcription factor NFkB, whose presence is a prerequisite
for the formation/action of cytokines/chemokines involved
in inflammatory reactions.
Therefore, these natural compounds can dampen the
inflammatory response, but also simultaneously reduce
oxidative stress, as observed by Umar et al. [13].
In recent years, extracts from the gum resin of BS have
been shown to target both the humoral and adaptive immune
responses [14] eventually interfering with the inflammatory
cascade [15].
However, to the best of our knowledge, no studies have
yet investigated whether the BS extracts can exert any effects
on specific T-cell subsets whose balance is crucial for the
maintenance of immune homeostasis: the regulatory T-
cells (Tregs) and the proinflammatory Th1/Th17 cells. In
the present study, different commercially available B. serrata
extracts were employed as follows: (i) to compare their
composition and in vitro antioxidant power; (ii) to test their
ability to modulate Treg/Th1/Th17 cells ex vivo.
2. Materials and Methods
2.1. Chemicals and PlantMaterial. All chemicals used were of
analytical reagent grade from Sigma-Aldrich (St. Louis, MO,
USA). Six (A, B, C, D, E, and F, resp.) of the seven BS oleogum
resins utilized in the present study were commercially avail-
able and were certified for a content of boswellic acids of 65%.
The pale yellow or white amorphous powders were insoluble
in water but soluble in methanol and dimethyl sulfoxide
(DMSO). The seventh (G) BS extract was an aqueous extract
obtained by a process of bioliquefaction based on enzyme
biocatalysis [16] and was kindly offered by its producer
(Phenbiox, Calderara di Reno, Bologna, Italy).
2.2. TLC Analysis. BS extract separation was performed on
20 × 20 cm silica gel plates with a fluorescent indicator at
254 nm (Sigma-Aldrich, St. Louis, MO, USA). Pentane and
diethyl ether (2 : 1) containing 1% (v/v) of acetic acid were
used as a mobile phase. Twenty mg of BS extracts was
dissolved in 300 𝜇L of ethanol, sonicated for 5 minutes, and
centrifuged. Clear supernatant (10 𝜇L) was carefully layered
at 1.5 cm from the bottom of the plate giving an elution
distance of 9 cm. After the separation, plates were observed
at 254 nm and developed with anisaldehyde (5mL) in glacial
acetic acid (50mL) and H
2
SO
4
(1mL). The TLC analysis of
BSG extract was not performed due to its particular formula-
tion.
2.3. HPLC-DAD Analysis. A HPLC system (Beckman Coul-
ter, Brea, CA, USA), comprising a 116 pump, a 507 auto-
matic autosampler, an UV-Diode Array 168 detector, and
integration software 32 Karat, was used for the analysis
of seven BS extracts. Samples were prepared by dissolving
extracts in methanol. Briefly, the separation was performed
using a reverse phase column Luna C18 5𝜇m 250 × 4.6mm
(Phenomenex, Torrance, CA, USA) with a guard column
PR C-18 5 𝜇m 15 × 4.6mm (Phenomenex, Torrance, CA,
USA). Chromatographic separation was achieved in isocratic
conditions at room temperature. The mobile phase was
a mixture of phosphoric acid (H
3
PO
4
10mM in water)
and acetonitrile (19 : 81 v/v). The flow rate was 1mL/min,
and the injection volume was 50 𝜇L. The analyses were
made at two different wavelengths (210 and 260 nm) and
UV spectra were recorded in the range of 190–300 nm. A
standard stock solution was prepared by dissolving 5mg
of AKBA analytical standard (Sigma-Aldrich, 5mg, batch
number BCBN2928V, CAS number 416619) in methanol
(5mL).The calibration curve was obtained by analyzing nine
serial dilutions (50 ppm, 25 ppm, 15 ppm, 10 ppm, 7.5 ppm,
5 ppm, 2.5 ppm, 1 ppm, and 0.5 ppm) of the stock solution
and by plotting the peak area measured at 260 nm against
AKBA concentrations. The following equation of the curve
was obtained:
𝑦 = 79739𝑥 − 5414, 𝑅2 = 0.999. (1)
The AKBA peaks were identified on the basis of the retention
time on the chromatogram at 260 nm. All measurements
were performed in triplicate and data were reported as mean
± SD.
2.4. Quantification of Total Phenolic Content (Folin-Ciocalteu
Method). The total content of polyphenolics was determined
by a colorimetric method as described by Singleton and
Rossi [17] and adapted to a 96-well plate format. Briefly, the
seven BS extracts were redissolved in 1mL of methanol and
100 𝜇L/well of each extract was dispensed into a flat bottom
96-well tissue culture plate (Becton Dickinson, Lincoln Park,
NJ); then 150𝜇L Folin-Ciocalteu reagent (1mL Folin-Denis’
reagent in 4mLH
2
O) was added.The plate was incubated for
10min at 37∘C. Next, 50𝜇L of a saturated Na
2
CO
3
solution in
H
2
O was added to each well and the plate was incubated for
a further 10min. The absorbance was measured at 765 nm.
A standard calibration curve was plotted using gallic acid
(0–300mg/L). The results were expressed as g of gallic acid
equivalents (GAE) per g of dry weight of BS extract. The
results were expressed as the average of three measurements.
2.5. Antioxidant Activity. Free radical scavenging activity
was studied using 1,1-diphenyl-2-picrylhydrazyl (DPPH) on
a microplate analytical assay according to the procedures
described by Srinivasan et al. [18], while the total radical
scavenging capacity of the same products was measured
by the 2,2-azinobis-(3-ethylbenzothiazoline-6-sulfonic acid)
(ABTS) assay as modified by Re et al. [19], for application to
a 96-well microplate assay.
Finally, the determination of antioxidant activity by
FRAP assay was carried out according to the procedure
described by Mu¨ller et al. [20], monitoring the reduction of
Fe3+-tripyridyl triazine (TPTZ) to blue-colored Fe2+-TPTZ.
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Trolox was used as standard in all assays and the ability of
BS extracts to scavenge the different radicals was expressed
as tocopherol-equivalent antioxidant capacity (mmol TE/g
of product) and, for DPPH and ABTS assays, also as IC
50
,
the latter defined as the concentration of the tested material
required to cause a 50% decrease in initial DPPH/ABTS con-
centration. All measurements were performed in triplicate
and reported as mean ± standard deviation (SD).
2.6. Immune Responses
2.6.1. Cell Proliferation Assay. Human peripheral blood
mononuclear cells (PBMCs) of seven healthy donors (HD;
5 male and 2 female, age mean ± standard deviation: 47 ±
12.1 years) were isolated from fresh heparinized venous
blood (10mL/HD) by gradient separation. The study was
approved by the local ethics committee (CEAS Umbria)
and written informed consent was obtained from par-
ticipants in accordance with the Declaration of Helsinki.
The final concentration of live cells was adjusted to 1 ×
106/mL in complete medium (RPMI-1640 medium contain-
ing 10% heat-inactivated serum, L-glutamine (2mM), Euro-
clone, penicillin (100U/mL), and streptomycin (100 𝜇g/
mL), BiochromAG, Berlin). PBMCs were stained with car-
boxyfluorescein diacetate succinimidyl ester (CFSE) cell
tracer (BioLegend, San Diego, CA), dispensed into flat bot-
tom 24-well tissue culture plates (Becton Dickinson, Lincoln
Park, NJ) (1mL/well), and cultured for 5 days at 37∘C in
5% CO
2
. For proliferation stimuli were either 1 𝜇g/mL of
pokeweed mitogen (PWM; Sigma-Aldrich Co. Ltd., Saint
Louis, Missouri) or 1.2 𝜇g/mL of phytohemagglutinin (PHA;
BiochromAG, Berlin), in the presence or absence of two BS
extracts (0.1 𝜇g/mL). BS extractA revealed the highest in vitro
antioxidant power; BS extract Gwas obtained with a different
extraction method compared to other BS compounds (by
Phenbiox srl). So lymphocytes were exposed, in the cul-
ture medium, to an AKBA concentration of 3.8 ng/mL that
resulted below the mean maximal concentration of 6 ng/mL
detected in human plasma after an oral administration of a
BS dry extract in fasted condition [21].
A negative control was represented by PBMC cultured
without any mitogen/extract (C), so that the base prolif-
eration could be estimated [22]. Therefore, nine different
experimental theses for each blood sample were tested.
Flow cytometry analyses were performed on a standard
FACSCalibur flow cytometer (BectonDickinson,Mountain
View, CA) running the CellQuestPro software. The results
of the lymphocyte proliferation assay were expressed as a
percentage (%). Furthermore, the lymphocyte proliferation
index (LPI) was calculated with the following formula:
LPI = (FP − BV)
BV
∗ 100, (2)
where the FP values are represented by the “final percentages”
of cell proliferation (after 5 days in culture with BSs and
with/without the mitogens), whereas the BV values are
represented by the “basal values” obtained by cells either
stimulated (with PHA and PWM) or not (CTR) with the
mitogen but without BSs [23].
2.6.2. Phenotypic Characterization of Peripheral Blood Mono-
nuclear Cells. PBMCs obtained from the seven volunteers
were seeded further (1× 106 cells/well) into additional flat bot-
tom24-well tissue culture plates and cultured,with orwithout
PHA, for 5 days at 37∘C in 5% CO
2
. After culture, six-hour
in vitro stimulation with 25 ng/mL phorbol 12-myristate 13-
acetate (PMA), 1 𝜇g/mL ionomycin, and 1 𝜇L/mL BD Golgi-
Plug (BDBiosciences) in completemediumwas performed.
For surface staining, fluorescein isothiocyanate (FITC), Pe-
Cy7, or APC labelled antihuman CD4, CD3, and CD25 and
respective isotypes were used (BD Biosciences, San Jose, CA,
USA, Immunotools). Then, cells were permeabilised with
0.1% saponin blocking buffer after 4% paraformaldehyde fix-
ation to perform intracellular staining with Alexa Fluor 647
or Phycoerythrin (PE) antihuman IL-17 and INF𝛾, and their
isotype controls were used (BD Biosciences).When required,
cells were permeabilised with commercially available Fork-
head box protein P3 stain buffer (BD Biosciences) for
intracellular staining with PE-labelled mAb to human FoxP3
and respective isotype controls [24]. Debris was excluded
by backgating to CD3 T-cells in forward scatter/side scatter
(FSC/SSC) plots. Samples were analyzed using FACSCalibur
flow cytometer (BD) and CellQuestPro software (BD).
2.7. Statistical Analysis. The results of immune responses are
reported as mean ± standard error of the mean (SEM) from
seven samples of different HD. The unpaired Student’s 𝑡-test
was used to compare biological data from controls with that
from BS A or BS G treated samples, respectively (GraphPad
Prism, 2007) [25]. 𝑝 values < 0.05 for two-tailed test were
considered statistically significant.
3. Results
3.1. TLC Chromatograms. The preliminary qualitative TLC
screening of the BS extracts is shown in Figure 1. The UV
analysis revealed two main spots visible in all samples, with
the exception of extract C. The first spot had a Rf of 0.16,
whereas the second spot had a Rf of 0.29. The use of the
AKBA standard (lane S) allowed for the identification of this
boswellic acid in the spot with Rf of 0.29. It is noticeable that
extract C lacked the first spot and presented only traces of
the spot corresponding to AKBA, while extract A presented
the greatest spot referring to AKBA. Extracts A and E
presented other components absorbing at 254 nm. Figure 1(b)
demonstrates the pattern obtained after dyeingwith anisalde-
hyde, heating, and color development. Similar profiles were
obtained for extracts B, D, E, and F. Instead, extract E was
characterized by a major number of spots; extract A lost
the spots at the higher Rf; and extract C was found to have
fewer components. The majority of samples shared the spots
detected at Rfs of 0.24, 0.32, 0.40, 0.46, and 0.60.
3.2. HPLC-DADAnalysis. At 260 nm, themajority of extracts
presented twomajor peaks: the first one, at Rt of 13.2min, and
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Rf = 0.29
Rf = 0.16
(a)
Rf = 0.78
Rf = 0.60
Rf = 0.51
Rf = 0.46
Rf = 0.40
Rf = 0.32
Rf = 0.28
Rf = 0.24
(b)
Figure 1: UVdetection at 254 nm (a) forUV-active boswellic acids. Chromatograms after dyeingwith anisaldehyde (b). Rf values are reported
for the most relevant spots. A–F: six different powder extracts of Boswellia serrata gum resin; S: 3-acetyl-11-keto-beta-boswellic-acid (AKBA)
analytical standard (Rf = 0.29).
Table 1: AKBA quantification in Boswellia serrata extracts. Data are
reported as mean ± SD (𝑛 = 3). Samples A–F = powder extracts,
sample G = hydroenzymatic extract.
Sample Concentration§ % in B. serrata extract#
A 38.30 ± 1.01 3.83 ± 0.10
B 17.18 ± 0.05 1.72 ± 0.005
C 3.08 ± 0.06 0.31 ± 0.01
D 24.35 ± 1.87 2.43 ± 0.19
E nd∗ nd
F 21.07 ± 0.16 2.11 ± 0.02
G 0.29 ± 0.04 0.03 ± 0.004
§AKBA concentration is expressed as mg/g of powder extract, with the
exception of sample G (mg/mL of hydroenzymatic extract); #AKBA percent-
age is expressed as g/100 g of powder extract, with the exception of sample G
(g/100mL of hydroenzymatic extract); ∗nd = not detectable.
the second one, identified as AKBA by the use of an analytical
standard, at Rt of 26min. Other minor peaks were also
present. AKBA concentrations for each sample, calculated on
the basis of the peak area and the calibration curve, are shown
in Table 1. Extract A presented significantly higher amounts
of AKBA as compared with the other samples. Extract C
presented only a small peak of AKBA andwas lacking the first
peak.
Other components in the BS extracts were visualized at
210 nm. The chromatograms of all the BS extracts analyzed
at the different wavelengths to highlight the variability of the
components present in the samples are reported in Figure 2.
3.3. Determination of Total Phenolic Content and Antioxidant
Capacity of Boswellia serrata Extracts. All the BS extracts
utilized in the present study exhibited a relatively low content
in phenolics ranging from 7.68±0.9mg gallic acid equivalent
(GAE)/g (extract A) to 0.11 ± 0.05mg GAE/g (aqueous
extract G) (Table 2). The chemical complexity of the extracts,
often mixtures of many compounds with differences in
functional groups, polarity, and chemical behavior, could
lead to scattered results, depending on the antioxidant test
employed. For these reasons, in the present study, the BS
extracts were screened for their free radical scavenging
and reducing properties through three test systems: (a) 1,1-
diphenyl-2-picrylhydrazyl (DPPH) radical scavenging, (b)
monitoring of the reduction power of Fe3+ (FRAP assay), and
(c) evaluating the total radical scavenging capacity (ABTS
assay). All the BS extracts analyzed showed relative radical
scavenging activities in all the assays employed, revealing
antioxidant powers lower (from 34 to nearly 580 times) than
that of Trolox (positive control, Table 2).
However, between the BS extracts investigated, the BS
extract A showed the highest scavenging reducing power and
the highest polyphenolic content.
3.4. Immunomodulatory Activity. The in vitro lymphocyte
proliferation (CFSE assay) was not influenced by the BS
extracts if cells were cultured without any activator (data not
shown) or if stimulated by PHA. However, when cells were
activated by PWM, the addition of BS extracts induced a
significantly higher lymphocyte response (Figures 3(a) and
3(b)). No significant differences were observed between the
two types of BSs for the LPI (Figures 3(c) and 3(d)).
The in vitro regulatory or Th1/Th17 proinflammatory
responses (Figures 4(d), 4(e), and 4(f)) were not significantly
modulated by the addition of the BS extracts when PBMCs
were triggered by PHA. Neither type of utilized extract (A
versus G) elicited an altered response.
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Figure 2: Chromatograms of Boswellia serrata extracts (BS) after HPLC-DAD analysis. BS (A)–(F) extracts were diluted 1 : 400 in methanol,
whereas, BS (G) extract was diluted 1 : 20 in methanol. The chromatogram of the AKBA analytical standard is also reported (H). The
absorbance (mAU) is reported on the 𝑦-axis, wavelength (nm) on 𝑥-axis, and the retention time (minutes) on the 𝑧-axis.
Table 2: In vitro radical scavenging activity and polyphenolic content of different Boswellia extracts.
Boswellia serrata
extracts
Polyphenols
mg GAE/g
DPPH ABTS FRAP
TEACa
𝜇mol TE/g
IC
50
b
𝜇g/ml
TEAC
𝜇mol TE/g
IC
50
𝜇g/ml
TEAC
𝜇mol TE/g
A 7.68 ± 0.9 31.8 ± 0.7 340.2 ± 3.5 151.8 ± 10.6 79.26 ± 1.8 66.89 ± 3.5
B 1.43 ± 0.5 4.48 ± 0.08 2416 ± 12.5 37.54 ± 2.5 320.30 ± 4.5 ND
C 0.56 ± 0.2 3.83 ± 0.08 2823 ± 27.5 1.92 ± 0.1 6250 ± 17.5 ND
D 1.09 ± 0.4 6.29 ± 0.12 1720 ± 13.8 27.8 ± 1.9 431.62 ± 6.5 ND
E 1.09 ± 0.3 5.41 ± 0.11 1998 ± 17.5 18.7 ± 1.2 641.75 ± 9.5 ND
F 0.96 ± 0.3 5.20 ± 0.15 2080 ± 22.5 20.6 ± 21.4 581.94 ± 8.5 ND
G 0.11 ± 0.05 1.85 ± 0.03 5820 ± 32.5 1.76 ± 0.1 6800 ± 22.5 ND
Positive control
Trolox 10.85 ± 0.2 3.01 ± 0.2
aTEAC = Trolox equivalent (TE) antioxidant concentration. bIC50 =The concentration of compound that affords a 50% reduction in the assay; GAE = gallic
acid equivalent. ND = not detectable.
6 Oxidative Medicine and Cellular Longevity
CFSE
n.s.
0
50
100
150
PB
M
C 
pr
ol
ife
ra
tio
n 
(%
)
PHA + BS GPHA PHA + BS A
(a)
CFSE
30
35
40
45
50
55
PB
M
C 
pr
ol
ife
ra
tio
n 
(%
)
PWM
p = 0.03 p = 0.02
A
B B
PWM + BS A PWM + BS G
(b)
n.s.PHA
BS GBS A
−0.08
−0.06
−0.04
−0.02
0.00
0.02
LP
I (
%
)
(c)
n.s.PWM
0.0
0.1
0.2
0.3
LP
I (
%
)
BS GBS A
(d)
Figure 3: Boswellia serrata (BS) extract (A or G) effects on lymphocyte proliferation assay. Data are shown as mean ± SEM of seven
independent experiments. PBMCs were cultured with phytohemagglutinin (PHA; graphics (a) and (c)) or pokeweed mitogens (PWM;
graphics (b) and (d)) and stained with carboxyfluorescein diacetate succinimidyl ester cell tracer (CFSE).The lymphocyte proliferation index
(LPI) was calculated as reported in the text. A,BDifferent letters for 𝑝 < 0.05. n.s. = not significant.
However, when cells were not PHA pulsed, an increase of
FOXP3+ cells was observed in PBMCs cultured with the BS
extracts. In particular, a tendency towards a higher number
of regulatory cells was observed for extract A (𝑝 = 0.079),
whereas extract G led to a significant increase of FOXP3+ cells
(𝑝 = 0.045; Figure 4(a)).
Furthermore, higher number ofTh17+ cells, although not
significant, was again observed when PBMCs were cultured
with the extract G (Figure 2(C)).
4. Discussion
The therapeutical efficacy of BS extracts has been extensively
investigated in arthritis, asthma, diabetes mellitus, colitis,
and cancer [26, 27] in light of their antioxidant and anti-
inflammatory activities [28]. Indeed, all these diseases share
a persistent dysregulation of redox status that contributes
to the intensity and duration of the inflammatory response
and therefore to the induction and perpetuation of chronic
inflammation.
It is noteworthy that the phytochemical content of B.
serrata oleogum resin is dependent on both the botanical
origin and the geographical origin [29]. Usually it consists
of 30–60% triterpenes (such as 𝛼- and 𝛽-boswellic acids,
lupeolic acid), 5–10% essential oils, and 20–35% polysaccha-
rides [30]. According to Singh et al. [31], in aqueous and
ethanolic extracts of B. serrata, it is possible to recognize
alkaloids, carbohydrates, phytosterols, terpenoids, phenolic
compounds, flavonoids, and tannins. However, other authors
found also glycosides, proteins, and saponins [32].
Furthermore, the wide variations of pharmacologically
active molecules in commercial BS formulations could sig-
nificantly affect the final product [33].
The first aim of this study was to perform a comparative
analysis on the composition of different dry and aqueous
extracts of B. serrata gum resin as a tool for the evaluation
of the quality of the extracts.
Combination of TLC and HPLC analyses can be con-
sidered as a multidimensional analytical approach combin-
ing fast qualitative screening with an accurate and precise
quantification of specific compounds.We decided to quantify
AKBA because the boswellic acid, characteristic and unique
to Boswellia genus, is considered the most effective, at least
in in vitro studies. When analyzed at 260 nm, four of the
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Figure 4: Boswellia serrata (BS) extract (A or G) effects on Treg (CD4+CD25+FOXP3+ cells),Th1 lymphocyte (INF𝛾+ cells), andTh17 cell (IL-
17+) responses. Data are shown as mean ± SEM of seven independent experiments. PBMCs were cultured in absence (controls, C; graphics
(a), (b), and (c)) or presence of mitogen (phytohemagglutinin, PHA; graphics (d), (e), and (f)) and with/without BS extracts. A,BDifferent
letters for 𝑝 < 0.05. n.s. = not significant.
seven samples presented comparable profiles, characterized
by the presence of two main peaks the second of which
corresponds to AKBA.The other components of BS extracts,
lacking the keto moiety, were visualized only at a less specific
wavelength (210 nm) as already reported [34]. The AKBA
concentrations detected in samples A, B, D, and F are similar
to those reported by other authors [30, 35], while those found
in extracts C and G were 10 or 100 times lower, respectively.
It can be hypothesized that extract C belongs to Boswellia
species other than B. serrata, due to a wrong botanical
identification by local producers. Indeed, it has already been
reported that the elution profile of Boswellia frereana gum
resin lacks KBA and AKBA peaks [34], while Boswellia sacra
gum resin contains much lower amounts of KBA and less
AKBA than B. serrata [34, 36]. Concerning extract G, this
aqueous extract showed a lower content of AKBA, but it
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was enriched by other components of the phytocomplex,
as demonstrated by the additional peaks obtained in the
elution profile at 210 nm.The presence of these compounds is
probably related to the particular and innovative extraction
method [16].
The composition of BS extract E is challenging, due to the
discrepant results in TLC and HPLC analysis. The spot at Rf
of 0.26, a putative AKBA component, was not confirmed by a
corresponding peak in the HPLC chromatogram at 260 nm.
Other components of the phytocomplexes containing a keto
moiety should have contributed to this spot and further
analyses are needed to identify these molecules.
The antioxidative potential and radical scavenging activ-
ity of aqueous and ethanolic extracts of B. serrata are
significantly correlated to their total phenolic and flavonoid
content [31].
According to Kohoude et al. [37], the amount of phe-
nolics in Boswellia genus (315 g/kg) is comparable to ref-
erence extracts rich in phenolic compounds. Despite what
is reported in literature, the BS samples investigated here
were all characterized by either relatively low antioxidant
properties or total phenolic content. Indeed, the latter ranged
from 0.11 ± 0.05 to 7.68 ± 0.9mg GAE/g versus values of
28.46–12.73mg GAE/g obtained by other authors in aqueous
and ethanolic extracts, respectively [31].
According to the extraction procedure, the antioxidant
activity increased with the polarity of the solvent. Other
authors reported that the essential oil ofBoswellia dalzieliiwas
characterized by low antioxidant activity [36] and that this
was due to the extraction method adopted (e.g., low polarity
of the solvent) that determined the absence of phenolics,
especially flavonoids.
In the present study, the extraction methods adopted
by manufacturers or even the preservative systems used
could be responsible for the low level of total phenolic and
flavonoids compounds, which are contained mainly in the
volatile essential oil component of the oleogum resin.
Furthermore, although theoretically the aqueous extract
(extract G) should have characteristics closest to the natural
product being obtained by an enzymatic hydrolysis that
maintains the intact phytocomplexes [16], we observed that it
was the one with the lowest antioxidant properties and total
phenolic contents.
However, these results are at least partially in line with
those of other authors reporting that the wild habitat samples,
with a completely different profile as compared to the market
samples, were those lacking antioxidant activity [28].
Nevertheless, the BS extracts of the present study were
able to significantlymodulate some immune responses inves-
tigated independently of the in vitro antioxidant activities. As
reported in Figure 3(b), when cells were stimulated by PWM,
a mitogen that stimulates B lymphocytes in the presence of
T-cells, the PBMC proliferation was significantly increased
(𝑝 < 0.05) by the addition of the BS extracts (0.1 𝜇g/mL for
both extracts A and G) and the LPI did not change between
the two BS extracts (Figure 3(d)).
Conversely, when cells were activated by PHA, neither
the PBMC proliferation (mainly, T-cells+) nor the LPI were
affected by the BS extracts (Figures 3(a) and 3(c)).
It has been previously reported that the BS could produce
opposing effects on immune responses in vivo or in vitro.
Potentially low concentrations of BSs increase stimulated
proliferation of lymphocytes whereas higher concentrations
are even inhibitory [14].
Sharma et al. [38] reported that a mixture of various
boswellic acids in the range of 1.95–125 𝜇g/mL inhibited mice
splenocytes stimulated with lipopolysaccharides (LPS), PHA,
alloantigen, and concanavalin A (ConA), in a concentration-
dependentmanner. Indeed, a significant inhibition of spleno-
cytes to mitogens and alloantigens was observed starting
from concentrations greater than 3.90 𝜇g/mL.
On the other hand, Gayathri et al. [15] observed that
30 𝜇g/mL of a crude methanolic BS extract is able to inhibit
almost 80% of human lymphocyte proliferation. These data
are in striking contrast with the observations of other authors
[39] who tested the effect of 1mg/mL of BS total alcoholic
extract, gum, or volatile oil on human lymphocyte prolifera-
tion and observed no inhibition of cells stimulatedwith either
PHA or Con A.
Besides the different lymphocyte proliferation assays
applied, the BS concentrations used in the present study were
10 to 1000 times lower than those adopted in the cited articles
and, at these doses, we obtained an effect on the lymphocyte
proliferation only when cells were stimulated by PWM (B
cells+).
However, in mice treated with orally administered
boswellic acids, the secondary antibody titres were appre-
ciably enhanced at the lowest tested doses (25mg/kg body
weight versus 100–200mg/kg) [38].
The dose of BS extracts we adopted was probably low
enough to induce an effect on B cells+ (activated by PWM),
but too low to induce an inhibition of T lymphocyte prolifer-
ation, as reported by other authors [14, 39].
In the maintenance of T-cell balance a pivotal role is
attributed to T-helper cells and regulatory T-cells [40, 41]. T-
helper cells are defined as Th1-, Th2-, or Th17-cells and are
characterized by differential expression of certain cytokines
[42]. Th1-cells have the capacity to express the key cytokine
interferon-𝛾 (IFN-𝛾), whereas Th17-cells, a more recently
described T-helper cell subset, evolutionally and functionally
divergent fromTh1 andTh2 cell subsets, are characterized by
their ability to produce interleukin-17A (IL-17A) [43].
Regulatory T-cells (Tregs) suppress effector T-cells and,
in humans, can be characterized by a CD4+CD25highFoxP3+
phenotype [41].
In our study, we observed that when PBMCs from
healthy controls were not activated by PHA mitogen, the
presence of BS extract G in the culture medium determined
a significant increase of Tregs (Figure 4(a)). Furthermore, the
increased number of Treg cells in BS G treated samples was
accompanied by a higher number, although not significant,
of Th17+ cells. Conversely, the BS extracts did not influence
the number ofTh1+ cells (INF𝛾+). When PBMCs were pulsed
by PHA, no additional effect could be seen following the BS
extract addition.
The recent evidence of a developmental plasticity between
Treg andTh17 cells prompts the investigation of intermediate
phenotypes that result from their reciprocal conversion
Oxidative Medicine and Cellular Longevity 9
according to the surrounding microenvironment [44]. The
presented results show a possible role for BS extracts in such
a fine balance between these two cell subsets.
Furthermore, it is important to note that, at least in mice,
Th17 lymphocytes can also function as B-cell helpers [45],
mediating B-cell differentiation and antibody class switch
recombination. The results of our lymphocyte proliferation
assay showed that the BS extracts exerted a significant
stimulatory effect on B+ cell proliferation, possibly mediated
by an enhanced number of Th17+ cells.
Many authors have demonstrated that B. serrata extracts
turn out to be effective in the treatment of diseases such
as inflammatory bowel disease and osteoarthritis in which
inflammation and/or oxidative stress exert an important
pathogenic role [2, 13, 30, 46].
However, BS extracts also exerted beneficial effects in
some autoimmune diseases, such as rheumatoid arthritis [1],
where chronic inflammation and an aberrant autoimmune
response are hallmarks of the disease [47].
This ex vivo study provides evidence that B. serrata
extracts, besides their reported capacity in dampening the
inflammatory response together with counteracting the
oxidative stress, were able to influence the regulatory and
effector T-cell compartments.
In order to draw conclusions, it will be necessary to
deepen the experiment on a wider case study. However,
these preliminary results suggest that frankincense should
be further investigated for its promising ability to inter-
fere, possibly also through such regulatory mechanism, on
immune dysregulation typical of various immune disorders,
but attention should be paid to the quality of the commercial
extracts which can show wide variations in their chemical
composition.
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